Pfizer Likes Consumer Business Fit As Segment Grows 8%

By Carolyn B. Phenicie / Email the Author / “The Tan Sheet” Feb. 6, 2012, Vol. 20, No. 06
OTCs / Word Count: 711 / Article # 05120206004

Executive Summary

Increased sales of core brands including Advil, Caltrate and Robitussin drove up consumer sales 8% to $817 million for Pfizer’s fourth quarter. CEO Ian Read sees the segment “fitting nicely” in Pfizer following its animal health and nutrition business divestments.

Purchase this Article

$50.00 Buy Now

For $50.00, purchase this 711-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Pfizer Likes Consumer Business Fit As Segment Grows 8%

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to “The Tan Sheet” will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Pfizer Likes Consumer Business Fit As Segment Grows 8%

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 3

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article